Michael Postow

Michael Postow, M.D., is Co-Lead Melanoma Disease Management Team at Memorial Sloan Kettering Cancer Center and assistant professor of medicine at Weill Cornell Medical College. Dr. Postow treats patients with advanced melanoma and was the principal investigator of a clinical trial that led to FDA approval of the nivolumab + ipilimumab immunotherapy combination to treat melanoma. He has published first or senior author publications related to melanoma and immunotherapy in the New England Journal of Medicine, Lancet Oncology, and Journal of Clinical Oncology and speaks at the US and international meetings about topics related to research and treatment of advanced melanoma.

Dr. Postow is currently leading clinical trials testing new immunotherapy combinations in patients with advanced melanoma, including as an investigator on Infinity’s MARIO-1 trial of IPI-549 in combination with Opdivo for which he brings tremendous insight in treating patients and into potential future paths for IPI-549 in melanoma.